Dr. Ludwig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Asst. Professor at MD Anderson Cancer Center, Dept. of Sarcoma Medical Oncology. Primary research focus on Ewing sarcoma and DSRCT.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2001
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2000 - Present
TX State Medical License 2006 - 2026- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Start of enrollment: 2025 Jan 31
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 2651 citationsTargeting multidrug resistance in cancerGergely Szakács, Jill K. Paterson, Joseph A. Ludwig, Catherine Booth-Genthe, Michael M. Gottesman
Nature Reviews. Drug Discovery. 2006-03-01 - 1140 citationsBiomarkers in cancer staging, prognosis and treatment selection.Joseph A. Ludwig, John N. Weinstein
Nature Reviews. Cancer. 2005-11-01 - 77 citationsComplete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor.Andrea Hayes-Jordan, Holly Green, Heather Lin, Pascal Owusu-Agyemang, Nancy E. Fitzgerald
Annals of Surgical Oncology. 2014-01-01
Journal Articles
- Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient SurvivalAlexander J Lazar, Joseph A Ludwig, Cynthia E Herzog, Raphael E Pollock, Clinical Cancer Research
- Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing SarcomaJoseph Ludwig IV, MD, Clinical Cancer Research
Press Mentions
- Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual MeetingNovember 11th, 2020
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020September 21st, 2020- MD Anderson Researchers Receive Over $25.5 Million in CPRIT FundingFebruary 23rd, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
